<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166549">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01980498</url>
  </required_header>
  <id_info>
    <org_study_id>MOLT-2013-02</org_study_id>
    <secondary_id>2013-001271-20</secondary_id>
    <nct_id>NCT01980498</nct_id>
  </id_info>
  <brief_title>PEctin Rapid Fentanyl Efficacy Clinical Trial For pAin at Swallowing Undergoing radioTherapy</brief_title>
  <acronym>PERFECT FAST</acronym>
  <official_title>Multicenter Randomized Open Trial to Evaluate Efficacy of Fentanyl Pectin Nasal Spray vs Physician Choice-Usual Care in Reducing Incidental Predictable Breakthrough Pain at Swallowing in Head/Neck Cancer Patients Undergoing Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>L.Molteni &amp; C. dei F.lli  Alitti-Soc. di Esercizio S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Consorzio Mario Negri Sud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>L.Molteni &amp; C. dei F.lli  Alitti-Soc. di Esercizio S.p.A.</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the present phase IIIb study is to assess the efficacy of FPNS
      compared with Physician Choice-Usual Care (PC-UC) in the management of swallowing IP-BTP in
      head and neck cancer patients undergoing radiotherapy with or without chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Population: In and out patients with head and neck cancer undergoing radiotherapy,
      regardless of the day of the radiotherapic treatment, with or without chemotherapy and
      treated with analgesic opioids at a stable dose equivalent to 60 mg oral morphine to control
      background pain but with uncontrolled pain at swallowing (moderate/severe intensity: ≥ 4 on
      a NRS 0-10).

      Study design: Patients that have signed the ICF and met inclusion and exclusion criteria are
      randomly assigned 1:1 to receive one of the following

      IP-BTP treatments:

        1. Fentanyl pectin nasal spray (FPNS)

        2. Physician choice-Usual Care (PC-UC) Each patient will assume the drug no more than 3
           episode a day (at main meals: breakfast, lunch and dinner) for 15 episodes in total in
           5/6 consecutive days. At each episode the patients will record the pain at baseline (
           before drug administration ), and 10, 20 30 minutes after assuming FPNS or PC-UC.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Difference in the mean intensity of IP-BTP related to swallowing from the baseline to 20 minutes after taking FPNS/PC-UC (PID20).</measure>
    <time_frame>up to 6 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The difference in the mean intensity of IP-BTP related to swallowing from the baseline to 10 and 30 minutes after assuming FPNS/PC-UC</measure>
    <time_frame>up to 6 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration of rescue therapy</measure>
    <time_frame>up to 6 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>up to 6 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's pain relief measured at the end of the study period through the 5-points numeric scale (0=none; 4=complete)</measure>
    <time_frame>Day 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Incidental Predictable Breakthrough Pain (IP-BTP)</condition>
  <arm_group>
    <arm_group_label>PecFent nasal spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients that have signed the ICF and met inclusion and exclusion criteria are randomly assigned 1:1 to receive one of the following IP-BTP treatments:
Fentanyl pectin nasal spray (FPNS)
Physician choice-Usual Care (PC-UC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physician choice-Usual Care (PC-UC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients that have signed the ICF and met inclusion and exclusion criteria are randomly assigned 1:1 to receive one of the following IP-BTP treatments:
Fentanyl pectin nasal spray (FPNS)
Physician choice-Usual Care (PC-UC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl pectin nasal spray (FPNS)</intervention_name>
    <description>The first dose of FPNS will be 100 mcg dose. It will be increased until 800 mcg dose.</description>
    <arm_group_label>PecFent nasal spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physician choice-Usual care (PC-UC)</intervention_name>
    <description>The PC-UC will be started at a dose according to the physician choice. If this dose of PC-UC is effective on pain control, at all the following meals the patient will take the same dose of PC-UC. If the dose of PC-UC results non effective on pain control, at the following meal the patient will take an increased dose of the same PC-UC drug or change the PC-UC drug, according to the physician choice.</description>
    <arm_group_label>Physician choice-Usual Care (PC-UC)</arm_group_label>
    <other_name>PC-UC is any drug used in clinical use for treating IP-BTP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female aged 18 years or over

          -  Diagnosis of stage III-IV cancer of oral cavity, oropharynx, hypopharynx, larynx,
             salivary gland cancer

          -  Receiving radiation therapy (RT) with or without concurrent platinum based
             chemotherapy or cetuximab as first line treatment or as postoperative adjuvant
             treatment

          -  Background pain managed with a stable fixed dose of opioid equivalent to 60mg oral
             morphine daily

          -  Uncontrolled pain (IP-BTP) during swallowing with an intensity ≥4 on an 11-point
             numeric scale (0=no pain; 10=worst possible pain). This pain will have to be measured
             with the ingestion of a solid/liquid food (depending on the ability to swallow or
             less solid foods of the patient at moment)

          -  Patients able to receive a nasal spray therapy

          -  Willing and able to sign an informed consent form

          -  Females with childbearing potential must provide a negative pregnancy test and both
             males and females must be using adequate contraception during the study

        Exclusion Criteria:

          -  Patients with known metastatic disease

          -  Known hypersensitivity to opioids, to Fentanyl or to drugs used in the PC-UC, and/or
             to study medications' formulation ingredients

          -  Patients with impaired chemistry laboratory exams, assessed as routine clinical
             practice before radiotherapy start:

               1. Hepatic function:

                  Total bilirubin &gt; 2 times the upper-normal limit (ULN) Serum transaminase &gt; 5
                  times ULN

               2. Renal function:

        Serum creatinine concentration &gt; 2 times ULN

          -  Pregnant or breastfeeding women

          -  Patients unlikely to comply with the protocol or unable to understand the nature,
             scope and possible consequences of the study

          -  Patients planned to receive other investigational treatments during study period

          -  Patients with moderate to severe respiratory impairment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Licitra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS - Istituto Nazionale Tumori - Milano (Italy)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Licitra, MD</last_name>
    <email>Lisa.Licitra@istitutotumori.mi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paolo Bossi, MD</last_name>
    <email>Paolo.Bossi@istitutotumori.mi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)</name>
      <address>
        <city>Meldola</city>
        <state>Forlì - Cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabetta Parisi</last_name>
    </contact>
    <investigator>
      <last_name>Elisabetta Parisi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto per la Ricerca e la Cura del Cancro a carattere Scientifico - IRCC</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Delmastro</last_name>
    </contact>
    <investigator>
      <last_name>Elena Delmastro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Mirano Azienda Ulss 13</name>
      <address>
        <city>Mirano</city>
        <state>Venezia</state>
        <zip>30035</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Azzarello</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Azzarello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Bellaria</name>
      <address>
        <city>Bologna</city>
        <zip>40139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Frezza</last_name>
    </contact>
    <investigator>
      <last_name>Giovanni Frezza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;Spedali civili&quot; di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michela Buglione</last_name>
    </contact>
    <investigator>
      <last_name>Michela Buglione</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce e Carlè</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nerina Denaro</last_name>
    </contact>
    <investigator>
      <last_name>Nerina Denaro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianpaolo Biti</last_name>
    </contact>
    <investigator>
      <last_name>Gianpaolo Biti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michela Marcenaro</last_name>
    </contact>
    <investigator>
      <last_name>Michela Marcenaro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Carlo Poma</name>
      <address>
        <city>Mantova</city>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabio Piazza</last_name>
    </contact>
    <investigator>
      <last_name>Fabio Piazza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniela Alterio</last_name>
    </contact>
    <investigator>
      <last_name>Daniela Alterio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Bossi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paolo Bossi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Italo Dell'Oca</last_name>
    </contact>
    <investigator>
      <last_name>Italo Dell'Oca</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda Ca' Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mauro Palazzi</last_name>
    </contact>
    <investigator>
      <last_name>Mauro Palazzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS - Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Caponigro</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Caponigro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Gemelli di Roma</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincenzo Valentini</last_name>
    </contact>
    <investigator>
      <last_name>Vincenzo Valentini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Marucci</last_name>
    </contact>
    <investigator>
      <last_name>Laura Marucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria della Misericordia</name>
      <address>
        <city>Rovigo</city>
        <zip>45100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Mandoliti</last_name>
    </contact>
    <investigator>
      <last_name>Giovanni Mandoliti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Città della Salute e della Scienza - Ospedale Dermatologico S. Lazzaro</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Airoldi</last_name>
    </contact>
    <investigator>
      <last_name>Mario Airoldi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Trento - Presidio Ospedaliero Santa Chiara</name>
      <address>
        <city>Trento</city>
        <zip>38122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Bolner</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Bolner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda U.L.S.S. 12 Veneziana</name>
      <address>
        <city>Venezia Mestre</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Grazia Ghi</last_name>
    </contact>
    <investigator>
      <last_name>Maria Grazia Ghi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 28, 2013</lastchanged_date>
  <firstreceived_date>October 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Pectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
